Pub Date : 2020-12-20DOI: 10.30683/1927-7229.2020.09.09
Jing Bai
{"title":"Serum Biomarkers Study and the Establishment of Diagnostic Models for Hepatitids B-Related HCC","authors":"Jing Bai","doi":"10.30683/1927-7229.2020.09.09","DOIUrl":"https://doi.org/10.30683/1927-7229.2020.09.09","url":null,"abstract":"","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"101 1","pages":"72-81"},"PeriodicalIF":0.0,"publicationDate":"2020-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72828090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-20DOI: 10.30683/1927-7229.2020.09.11
S. Nagaraj
Background: Lung is the main organ at risk for radiation induced injury while treating breast cancers with Post Mastectomy Radiotherapy (PMRT). Restrictive lung changes are usually seen in spirometry which tends to normalize by 1 year. Central Lung Distance (CLD) is shown to correlate well with the percentage of ipsilateral lung volume irradiated. Aims and Objectives: Spirometric changes following Radiation Therapy (RT) to chest wall in breast cancer patients using conventional fractionation and its correlation with acute radiation pneumonitis. Materials and Methodology: Thirty Breast cancer patients who received RT to chest wall +/supraclavicular fossa and axilla, following Modified Radical Mastectomy (MRM) and neoadjuvant or adjuvant chemotherapy using tangential beams with Co60 teletherapy to a dose of 50 Gray in conventional fractionation were included and followed up till 6 months post RT. Baseline chest X-ray and spirometry done pre-RT were compared with those taken at 1, 3 and 6 months after completion of RT. Patients were evaluated at each visit for signs and symptoms of radiation pneumonitis, when present were graded as per Radiation Therapy Oncology Group (RTOG) criteria. Results: There was a significant fall in Forced Vital Capacity (FVC) by the end of 3 months (p value <0.01) which improved by 6 months without any active intervention in 95% of the patients. Mean baseline FVC was 83% which decreased to 70% by the end of 3 months and 79% at 6 months. Forced Expiratory Volume in first second (FEV1) and FEV1/FVC did not show any significant change compared to baseline. Spirometric changes correlated with reversible restrictive lung changes. One out of 30 patients developed symptomatic acute radiation pneumonitis (5%) of grade 3 severity who had moderate restrictive lung disease. Conclusion: Significant decrease in FVC of the lungs is present following PMRT in carcinoma of breast patients in the initial 3 months which tends to normalize by 6 months. 5% of the patients develop symptomatic acute lung toxicity which can be further reduced by minimizing the irradiated lung volume.
{"title":"Changes in Pulmonary Function and Development of Clinical Radiation Pneumonitis in Breast Cancer Patients following Post Mastectomy Radiation Therapy","authors":"S. Nagaraj","doi":"10.30683/1927-7229.2020.09.11","DOIUrl":"https://doi.org/10.30683/1927-7229.2020.09.11","url":null,"abstract":"Background: Lung is the main organ at risk for radiation induced injury while treating breast cancers with Post Mastectomy Radiotherapy (PMRT). Restrictive lung changes are usually seen in spirometry which tends to normalize by 1 year. Central Lung Distance (CLD) is shown to correlate well with the percentage of ipsilateral lung volume irradiated. Aims and Objectives: Spirometric changes following Radiation Therapy (RT) to chest wall in breast cancer patients using conventional fractionation and its correlation with acute radiation pneumonitis. Materials and Methodology: Thirty Breast cancer patients who received RT to chest wall +/supraclavicular fossa and axilla, following Modified Radical Mastectomy (MRM) and neoadjuvant or adjuvant chemotherapy using tangential beams with Co60 teletherapy to a dose of 50 Gray in conventional fractionation were included and followed up till 6 months post RT. Baseline chest X-ray and spirometry done pre-RT were compared with those taken at 1, 3 and 6 months after completion of RT. Patients were evaluated at each visit for signs and symptoms of radiation pneumonitis, when present were graded as per Radiation Therapy Oncology Group (RTOG) criteria. Results: There was a significant fall in Forced Vital Capacity (FVC) by the end of 3 months (p value <0.01) which improved by 6 months without any active intervention in 95% of the patients. Mean baseline FVC was 83% which decreased to 70% by the end of 3 months and 79% at 6 months. Forced Expiratory Volume in first second (FEV1) and FEV1/FVC did not show any significant change compared to baseline. Spirometric changes correlated with reversible restrictive lung changes. One out of 30 patients developed symptomatic acute radiation pneumonitis (5%) of grade 3 severity who had moderate restrictive lung disease. Conclusion: Significant decrease in FVC of the lungs is present following PMRT in carcinoma of breast patients in the initial 3 months which tends to normalize by 6 months. 5% of the patients develop symptomatic acute lung toxicity which can be further reduced by minimizing the irradiated lung volume.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84194699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-20DOI: 10.30683/1927-7229.2020.09.05
Donald Rozario
: The antibiotic salinomycin (SM) acts as a selective potassium ionophore. In budding yeast ( Saccharomyces cerevisiae ), we describe that the agent inhibits cell growth, elevates reactive oxygen species (ROS) levels and prominently causes mitochondrial damage, as revealed by the emergence of perpetually respiration-defective cells. The collection of systematic gene deletions in haploid yeast was screened to characterize genes whose deletion confers SM sensitivity or resistance if glycerol is provided as the only carbon source, thus requiring active respiration for growth. Mutants conferring the highest SM resistance were those of the Mms2-Ubi13 E2-ubiquitin conjugating enzyme (Lys63 polyubiquitination) and the TORC pathway, such as Sch9. Sch9 phosphorylation is reduced after SM treatment and, whereas initial SM-enhanced ROS levels are not diminished in the mutant, we suggest that a protective response is mounted in the absence of Sch9 that promotes mitochondrial stability under conditions of potassium ion loss. As indicated by other isolated mutants with altered SM sensitivity, levels and modifications of ribosomal proteins may also play a role in these responses. SM has attracted considerable attention due to its cancer stem-cell specific mode of action. Even if not all of its cancer stem cell targets may have an equivalent in yeast, these studies may suggest strategies for mitigating its side effects during treatment of cancer patients.
{"title":"A Yeast Mutant Screen Identifies TORC and Lys63 Polyubiquitination Pathway Genes among Determinants of Sensitivity to the Cancer Stem Cell-Specific Drug Salinomycin","authors":"Donald Rozario","doi":"10.30683/1927-7229.2020.09.05","DOIUrl":"https://doi.org/10.30683/1927-7229.2020.09.05","url":null,"abstract":": The antibiotic salinomycin (SM) acts as a selective potassium ionophore. In budding yeast ( Saccharomyces cerevisiae ), we describe that the agent inhibits cell growth, elevates reactive oxygen species (ROS) levels and prominently causes mitochondrial damage, as revealed by the emergence of perpetually respiration-defective cells. The collection of systematic gene deletions in haploid yeast was screened to characterize genes whose deletion confers SM sensitivity or resistance if glycerol is provided as the only carbon source, thus requiring active respiration for growth. Mutants conferring the highest SM resistance were those of the Mms2-Ubi13 E2-ubiquitin conjugating enzyme (Lys63 polyubiquitination) and the TORC pathway, such as Sch9. Sch9 phosphorylation is reduced after SM treatment and, whereas initial SM-enhanced ROS levels are not diminished in the mutant, we suggest that a protective response is mounted in the absence of Sch9 that promotes mitochondrial stability under conditions of potassium ion loss. As indicated by other isolated mutants with altered SM sensitivity, levels and modifications of ribosomal proteins may also play a role in these responses. SM has attracted considerable attention due to its cancer stem-cell specific mode of action. Even if not all of its cancer stem cell targets may have an equivalent in yeast, these studies may suggest strategies for mitigating its side effects during treatment of cancer patients.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91057580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-20DOI: 10.30683/1927-7229.2020.09.08
J. Bai
The retinoblastoma (Rb1) gene is one of the most important tumor suppressor genes. Dysfunction of Rb protein drives tumorigenesis by overcoming barriers to cellular proliferation. Consequently, factors modulating Rb function are of great clinical import. Here, we show that miR-26a was differentially expressed in human retinoblastoma cells, tissues and serums from retinoblastoma patients, compared with human retinal microvascular endothelial cells, non-tumor tissues and serums from healthy children, and that it tightly regulated the expression of Rb1 by specifically targeting a conserved sequence motif in its 3′ UTR, leading to low expression of Rb1. In vitro experiments determined that miR-26a directly participated in the regulation of cell proliferation of human Y79 RB cells. Our results also suggest that curcumin modulated the miR-26a expression profile, thereby exerting its anti-proliferation effects on Y79 RB cells via up-regulation of Rb1. To our knowledge, these data indicate for the first time that miR-26a directly regulates cell proliferation by targeting Rb1 in retinoblastoma and that miR-26a could be a potential therapeutic approach for retinoblastoma.
{"title":"Curcumin Inhibits Retinoblastoma Cell Proliferation by miR-26a Targeting the Tumor Suppressor Gene Rb1 in Y79 Cells","authors":"J. Bai","doi":"10.30683/1927-7229.2020.09.08","DOIUrl":"https://doi.org/10.30683/1927-7229.2020.09.08","url":null,"abstract":"The retinoblastoma (Rb1) gene is one of the most important tumor suppressor genes. Dysfunction of Rb protein drives tumorigenesis by overcoming barriers to cellular proliferation. Consequently, factors modulating Rb function are of great clinical import. Here, we show that miR-26a was differentially expressed in human retinoblastoma cells, tissues and serums from retinoblastoma patients, compared with human retinal microvascular endothelial cells, non-tumor tissues and serums from healthy children, and that it tightly regulated the expression of Rb1 by specifically targeting a conserved sequence motif in its 3′ UTR, leading to low expression of Rb1. In vitro experiments determined that miR-26a directly participated in the regulation of cell proliferation of human Y79 RB cells. Our results also suggest that curcumin modulated the miR-26a expression profile, thereby exerting its anti-proliferation effects on Y79 RB cells via up-regulation of Rb1. To our knowledge, these data indicate for the first time that miR-26a directly regulates cell proliferation by targeting Rb1 in retinoblastoma and that miR-26a could be a potential therapeutic approach for retinoblastoma.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82564282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-20DOI: 10.30683/1927-7229.2020.09.07
Zahra Jabbarpour
Stem cells have great potential to be applied as a treatment for various types of disorders. These cells exert therapeutic effects by modulating the immune system with the capability to secrete cytokines and chemokines. Previous studies have indicated that stem cells could be used as a therapeutic agent for different complaints, such as gastrointestinal diseases. For a long time now, researchers have moved toward stem cells' clinical application in this context. With the increasing number of trials in stem cell therapy of gastrointestinal disease, it is now time to evaluate these clinical trials' status. This paper reviews clinical trials that have used stem cells for the treatment of gastrointestinal tract diseases.
{"title":"Trends of Stem Cell-Based Clinical Trials in Gastrointestinal Tract Diseases","authors":"Zahra Jabbarpour","doi":"10.30683/1927-7229.2020.09.07","DOIUrl":"https://doi.org/10.30683/1927-7229.2020.09.07","url":null,"abstract":"Stem cells have great potential to be applied as a treatment for various types of disorders. These cells exert therapeutic effects by modulating the immune system with the capability to secrete cytokines and chemokines. Previous studies have indicated that stem cells could be used as a therapeutic agent for different complaints, such as gastrointestinal diseases. For a long time now, researchers have moved toward stem cells' clinical application in this context. With the increasing number of trials in stem cell therapy of gastrointestinal disease, it is now time to evaluate these clinical trials' status. This paper reviews clinical trials that have used stem cells for the treatment of gastrointestinal tract diseases.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76491373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-20DOI: 10.30683/1927-7229.2020.09.06
W. Tan
{"title":"Geometric Changes in the Parotid, Submandibular, and Thyroid Glands during Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma: A Cohort Study","authors":"W. Tan","doi":"10.30683/1927-7229.2020.09.06","DOIUrl":"https://doi.org/10.30683/1927-7229.2020.09.06","url":null,"abstract":"","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"24 1","pages":"46-55"},"PeriodicalIF":0.0,"publicationDate":"2020-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78235941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-12DOI: 10.30683/1927-7229.2020.09.03
K. Ina, Yuu Hosoe, Kazuhiro Ito, Miho Tatematsu, Masako Sakakibara, Megumi Kabeya, S. Kayukawa, Yoshihiro Ohta
The present study investigated the cancer prevalence and anticancer treatment patients undergoing hemodialysis at Nagoya Memorial Hospital. We retrospectively analyzed 663 patients undergoing hemodialysis between September 2014 and August 2019, including patient characteristics such as age, sex, and underlying diseases, cancer type, and cancer treatment. Seventy-eight patients (11.9%) of the dialysis population were diagnosed with cancer. Cancer type was then compared between registered cancer patients undergoing maintenance dialysis (N = 78) and non-dialysis controls (N = 3279) during the same period. Colorectal carcinoma is the most common malignancy diagnosed in our hospital, accounting for approximately 15% of all types of cancers. The data of anticancer treatment for this disease were compared between dialysis patients (N = 15) and controls (N = 563), whose clinical stages were defined according to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Since the need to administer chemotherapeutic agents to dialysis patients with colorectal carcinoma will increase, oncologists should collaborate with nephrologists to cautiously manage anticancer treatment to avoid severe toxicities.
{"title":"A Retrospective Survey of Patients Undergoing Maintenance Hemodialysis vis-à-vis Cancer Prevalence","authors":"K. Ina, Yuu Hosoe, Kazuhiro Ito, Miho Tatematsu, Masako Sakakibara, Megumi Kabeya, S. Kayukawa, Yoshihiro Ohta","doi":"10.30683/1927-7229.2020.09.03","DOIUrl":"https://doi.org/10.30683/1927-7229.2020.09.03","url":null,"abstract":"The present study investigated the cancer prevalence and anticancer treatment patients undergoing hemodialysis at Nagoya Memorial Hospital. We retrospectively analyzed 663 patients undergoing hemodialysis between September 2014 and August 2019, including patient characteristics such as age, sex, and underlying diseases, cancer type, and cancer treatment. Seventy-eight patients (11.9%) of the dialysis population were diagnosed with cancer. Cancer type was then compared between registered cancer patients undergoing maintenance dialysis (N = 78) and non-dialysis controls (N = 3279) during the same period. Colorectal carcinoma is the most common malignancy diagnosed in our hospital, accounting for approximately 15% of all types of cancers. The data of anticancer treatment for this disease were compared between dialysis patients (N = 15) and controls (N = 563), whose clinical stages were defined according to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Since the need to administer chemotherapeutic agents to dialysis patients with colorectal carcinoma will increase, oncologists should collaborate with nephrologists to cautiously manage anticancer treatment to avoid severe toxicities.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"157 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83958621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-25DOI: 10.30683/1927-7229.2018.07.04.1
Mohamed A. A. A. Hegazi
: Introduction : The detection of the multicentericity of thyroid cancer is essential to provide the appropriate surgical decision for the patients aiming to decrease the rate of redo surgery and recurrence Methods : A cohort study was conducted at the surgical unit of the oncology center, Mansoura university on fifty patients with well-differentiated thyroid cancer, all of them underwent total thyroidectomy then entire gland dissection technique for histopathological examination. Results : Preoperative radiology revealed unicentric suspicious nodules in 40 cases (80%) and no suspicious nodules in 10 cases (20%). Among the ten patients those showed no suspicious nodules radiologically, multicentricity was confirmed in 5 patients (50%) pathologically, and unicentric tumors was seen in 5 patients (50%). FNAC was done in the 40 mentioned cases and was diagnostic for them as papillary thyroid carcinoma. Among many variants of prediction during searching for the true incidence of multicentricity, only isthmic invasion and, the extra thyroid extension were the significant variants. Conclusion : Among many variants of prediction during searching for the true incidence of multicentricity, only isthmic invasion and, the extra thyroid extension were the significant variants.
{"title":"The Predictors of Multicentricity in Well-Differentiated Thyroid Cancer","authors":"Mohamed A. A. A. Hegazi","doi":"10.30683/1927-7229.2018.07.04.1","DOIUrl":"https://doi.org/10.30683/1927-7229.2018.07.04.1","url":null,"abstract":": Introduction : The detection of the multicentericity of thyroid cancer is essential to provide the appropriate surgical decision for the patients aiming to decrease the rate of redo surgery and recurrence Methods : A cohort study was conducted at the surgical unit of the oncology center, Mansoura university on fifty patients with well-differentiated thyroid cancer, all of them underwent total thyroidectomy then entire gland dissection technique for histopathological examination. Results : Preoperative radiology revealed unicentric suspicious nodules in 40 cases (80%) and no suspicious nodules in 10 cases (20%). Among the ten patients those showed no suspicious nodules radiologically, multicentricity was confirmed in 5 patients (50%) pathologically, and unicentric tumors was seen in 5 patients (50%). FNAC was done in the 40 mentioned cases and was diagnostic for them as papillary thyroid carcinoma. Among many variants of prediction during searching for the true incidence of multicentricity, only isthmic invasion and, the extra thyroid extension were the significant variants. Conclusion : Among many variants of prediction during searching for the true incidence of multicentricity, only isthmic invasion and, the extra thyroid extension were the significant variants.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85442717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-25DOI: 10.30683/1927-7229.2018.07.04.2
P. Shenoy
Metastases of breast cancer cells from the tissue of origin to distant sites including vital organs commonly occurs in patients suffering from breast cancer. Such metastases are detrimental to the quality of life of these patients. Clinical pathologists and basic researchers in the field of oncology commonly use techniques like immunohistochemistry to detect disseminated cancer cells in metastasized regions in an attempt to improve patient outcomes. This review sheds light on genotypic and phenotypic changes in disseminated cancer cells that occur during the ongoing process of metastasis, thereby leading to continuous changes in the expression levels of different markers expressed by these cells and making the immunohistochemical detection of breast cancer cells in the non-cognate tissues difficult.
{"title":"Why is Immunohistochemical Detection of Metastasized Breast Cancer Cells in the Immunocompetent Host Not Always Easy?","authors":"P. Shenoy","doi":"10.30683/1927-7229.2018.07.04.2","DOIUrl":"https://doi.org/10.30683/1927-7229.2018.07.04.2","url":null,"abstract":"Metastases of breast cancer cells from the tissue of origin to distant sites including vital organs commonly occurs in patients suffering from breast cancer. Such metastases are detrimental to the quality of life of these patients. Clinical pathologists and basic researchers in the field of oncology commonly use techniques like immunohistochemistry to detect disseminated cancer cells in metastasized regions in an attempt to improve patient outcomes. This review sheds light on genotypic and phenotypic changes in disseminated cancer cells that occur during the ongoing process of metastasis, thereby leading to continuous changes in the expression levels of different markers expressed by these cells and making the immunohistochemical detection of breast cancer cells in the non-cognate tissues difficult.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80374338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.06
Á. Romera
: Purpose of the Review : The aim of the review is to summarize the current evidence of HE4 tumor marker as a prognostic marker of endometrial cancer since it is a novel and not yet validated marker in the management of this neoplasm. Recent Findings : HE4 has been studied as a preoperative prognosis marker and the result is encouraging as it is statistically related to unfavorable prognostic markers in endometrial cancer. Having a preoperative marker that relates with prognosis is a non invasive and cost-effective way to classify the patients before the surgery act. Summary : Clinicians could use HE4 as a prognostic marker to help them in the preoperative decision-making process. Thus, good prognostic patients with a low serum HE4 could have a less invasive surgery avoiding lymphadecnectomy which decrease the morbidity of the procedure and reducing the operative time.
{"title":"Preoperative HE4 Tumor Marker and Prognostic Factors in Endometrial Cancer: Review Article","authors":"Á. Romera","doi":"10.30683/1927-7229.2019.08.06","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.06","url":null,"abstract":": Purpose of the Review : The aim of the review is to summarize the current evidence of HE4 tumor marker as a prognostic marker of endometrial cancer since it is a novel and not yet validated marker in the management of this neoplasm. Recent Findings : HE4 has been studied as a preoperative prognosis marker and the result is encouraging as it is statistically related to unfavorable prognostic markers in endometrial cancer. Having a preoperative marker that relates with prognosis is a non invasive and cost-effective way to classify the patients before the surgery act. Summary : Clinicians could use HE4 as a prognostic marker to help them in the preoperative decision-making process. Thus, good prognostic patients with a low serum HE4 could have a less invasive surgery avoiding lymphadecnectomy which decrease the morbidity of the procedure and reducing the operative time.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"136 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73493217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：